Related Experiment Videos
LEF1-mediated MMP13 gene expression is repressed by SIRT1 in human chondrocytes
Jinan Elayyan1, Eun-Jin Lee2, Odile Gabay3
1Laboratory of Cartilage Biology, Institute of Dental Sciences, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Summary
Sirtuin 1 (SIRT1) represses matrix metalloproteinase 13 (MMP13) in osteoarthritis by inhibiting the transcription factor LEF1. This finding offers new insights into cartilage degradation and potential therapeutic targets for osteoarthritis.
Area of Science:
- Biochemistry
- Molecular Biology
- Osteoarthritis Research
Background:
- Osteoarthritis (OA) is characterized by cartilage degradation, linked to reduced SIRT1 activity and increased MMP13 expression.
- LEF1 transcriptional activity enhances MMP13 expression, contributing to cartilage matrix loss in OA.
Purpose of the Study:
- To investigate the role of SIRT1 in regulating LEF1-mediated MMP13 gene expression in human OA chondrocytes.
- To elucidate the mechanism by which SIRT1 influences MMP13 expression in the context of OA.
Main Methods:
- Overexpression and knockdown of SIRT1 in human OA chondrocytes.
- Treatment with resveratrol (SIRT1 activator) and nicotinamide (NAM, SIRT1 inhibitor).
- IL-1β challenge to mimic OA conditions, followed by SIRT1 overexpression.
- Luciferase reporter assays to assess LEF1 transcriptional activity.
- Analysis of LEF1 and MMP13 protein and mRNA levels.
- Examination of mouse articular cartilage from Sirt1 knockout mice.
Main Results:
- SIRT1 overexpression or activation reduced MMP13 levels and activity.
- SIRT1 inhibition increased MMP13 expression.
- IL-1β challenge increased LEF1 and MMP13 expression, effects blunted by SIRT1 overexpression.
- SIRT1 repressed LEF1 protein and mRNA expression, reducing its transcriptional activity.
- Sirt1 knockout mouse cartilage showed elevated LEF1 and MMP13 levels, mirroring human OA cartilage.
Conclusions:
- SIRT1 represses MMP13 expression in human OA chondrocytes.
- This repression is mediated, at least partly, by SIRT1 inhibiting the transcription factor LEF1.
- SIRT1 acts as a negative regulator of MMP13, potentially through LEF1, offering a novel therapeutic target for OA.